CEO pay league table: biotech hero beats big pharma bosses
This article was originally published in Scrip
Who was the top-paid big pharma executive among in 2012? If you discount Johnson & Johnson's William Weldon, who stood down as CEO in April but continued as chairman until 28 December, taking home $29.8m in total compensation, then it was a near tie, but Abbott Laboratories' Miles White on $25.1m was pipped to the post by Pfizer's Ian Read with $25.6m.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.